Probiodrug AG is a Germany-based biopharmaceutical company active in the biotechnology & medical research industry. The Company is focused on the research and development of therapeutic products for the treatment of Alzheimer’s disease. It develops drugs to target toxic pyroglutamate-Abeta (pGlu-Abeta) via two modes of action, by inhibiting the production of pGlu-Abeta; and clearing existing pGlu-Abeta from the brain. The Company develops specific inhibitors for the enzyme Glutaminyl Cyclase (QC) helping in the creation of pGlu-Abeta and engineers a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Probiodrug AG’s pipeline includes the molecule inhibitors PQ912, PQ1565 and a monoclonal antibody PBD-C06.